Senior industry leaders shared their insights
For all the disruption it has brought in its wake, the Covid-19 pandemic has had many positive impacts for the global pharmaceutical industry, unleashing a wave of innovation in drug development that will bring significant benefits to patients. Faced with the prospect of delayed or cancelled clinical trials, the previously slow adoption of enabling technologies and more virtual and remote approaches to clinical trials shifted into higher gear, and the industry’s long-held ambition to ‘reshape clinical trials around the needs of patients’ moved from a distant goal to a current reality. The challenge now will be to build on this momentum, addressing key challenges to ensure that the full benefits and value of virtualisation and patient centricity are realised.
Hosted by the Financial Times in partnership with Medidata, this FT Digital Dialogue dived deep into how leading pharma companies have re-evaluated and recalibrated their approach to clinical trials during the pandemic. What has been their experiences, and those of their patients, of running trials remotely, and their appraisal of the benefits, opportunities and operational challenges? One year on, what has changed and what is yet to come?
World-class business leaders and speakers
Why attend?
Understand
The big picture, not just the individual strands of the business you work in
Connect
And build relationships with some of the biggest names in your industry
Discover
New approaches and strategies to help win market share
"An incredibly well-curated event. A great combination of thought-provoking discussions and networking."
Chanelle Duley University of Auckland
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice